BRAF and colorectal carcinoma: Interestingly, combination therapy of BRAF inhibition (encorafenib) and anti-EGFR monoclonal antibodies (cetuximab) has been well validated and approved by FDA in BRAF V600E-mutated metastatic COADREAD patients (BEACON CRC) (Kopetz et al., 2019).